Back to Journals » Medical Devices: Evidence and Research » Volume 5

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study

Authors Adelman D, Burgess A, Davies

Received 6 September 2012

Accepted for publication 1 November 2012

Published 14 December 2012 Volume 2012:5 Pages 103—109

DOI https://doi.org/10.2147/MDER.S37831

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Daphne T Adelman,1 Andrea Burgess,2 Philippa R Davies,3

1
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Neuroendocrine Tumor Department, The Christie, Manchester, UK; 3Neuroendocrine Tumor Unit, Royal Free Hospital, London, UK


Abstract: The somatostatin analogs (SSAs) lanreotide Autogel/Depot and octreotide long-acting release are used to treat acromegaly and neuroendocrine tumors. The present study evaluated opinions on SSA injection devices, including a recently approved lanreotide new device (lanreotide-ND), among nurses in Europe and the USA. Nurses injecting SSAs for at least three patients per year (n = 77) were interviewed regarding SSA devices. Device attributes were rated via questionnaire; nurses were then timed administering test injections with lanreotide-ND and octreotide long-acting release. The most important delivery system attributes were easy/convenient preparation and injection (ranked in the top five by 70% of nurses), low clogging risk (58%), and high product efficacy (55%). Compared with the octreotide long-acting release device, lanreotide-ND scored higher on 15/16 attributes, had shorter mean preparation and administration time (329 versus 66 seconds, respectively; P ≤ 0.01) and a higher overall preference score (70 versus 114, respectively; P ≤ 0.01). The five most important lanreotide-ND attributes were: prefilled device, confidence a full dose was delivered, low clogging risk, easy/convenient preparation and injection, and fast administration. These device features could lead to improvements in clinical practice and benefit patients/caregivers who administer SSAs at home.

Keywords: nurse, somatostatin analog, device, lanreotide, octreotide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]